Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
54.15
-0.48 (-0.88%)
At close: Sep 18, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$754,676
Profits / Employee
$147,929
Market Cap
346.31B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Veradigm | 2,300 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Elite Pharmaceuticals | 65 |
| CytoDyn | 14 |
Roche Holding AG News
- 1 day ago - CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents - TheFly
- 1 day ago - CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis - GlobeNewsWire
- 1 day ago - Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center - Business Wire
- 1 day ago - Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases - GlobeNewsWire
- 2 days ago - Genentech reports CELESTIMO study meets primary endpoint - TheFly
- 2 days ago - Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study - GlobeNewsWire
- 2 days ago - Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study - Business Wire
- 5 days ago - Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint - TheFly